Can anything shut down the Gold rally?
NAPLES/LONDON - Pentwater Capital Management LP has increased its stake in Ondine Biomedical Inc to 4.002% of outstanding shares, according to a regulatory filing published Thursday.
The Naples, Florida-based investment firm crossed the reporting threshold on September 3, 2025, raising its position from a previously reported 3.679%. The stake is held entirely through financial instruments with cash settlement, specifically swap contracts representing 20,746,666 shares.
The notification, filed under standard major holdings disclosure requirements, indicates that Pentwater’s position is controlled by Matthew Halbower through MCH PWCM Holdings Inc.
Ondine Biomedical, a non-UK issuer, disclosed the change in shareholding through a regulatory news service announcement. The filing shows that the threshold crossing was reported to the company on the same day it occurred.
The disclosure was made in accordance with financial regulatory requirements that mandate investors to report when their holdings cross certain thresholds.
Based on the press release statement, Pentwater now holds just over 4% of the effective economic interest in Ondine Biomedical through derivative instruments rather than direct share ownership.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.